Background {#Sec1}
==========

Survival of an organism in the face of either internal or external events requires a measured and appropriate stress response. It has been hypothesised that an abnormal stress response is linked to the development and subsequent severity of multi-organ failure \[[@CR1]\]. The stress response is coordinated by the primitive brain structures of the diencephalon and brainstem. It comprises a broad range of behavioural, neurohormonal, cardiovascular and other effects aimed at maintaining homeostasis. This biological system, developed over millions of years, is a critical requirement for the survival of organisms ranging from invertebrates to human beings. Conservation of this system across such a wide variety of species points to its success in priming organisms to respond to both internal and external change. In humans, stress is an indispensable part of learning and development, both physiologically and psychologically. However, when there is no escape from an inciting event, the stress response is prolonged and necessitates physiological or behavioural change in order to compensate and maintain stability. These changes themselves may generate sequelae or even complications for the organism. This is exemplified by the chronic stress-related diseases of hypertension, stroke, obesity and the metabolic syndrome \[[@CR2]\].

Illnesses commonly treated in intensive care represent significant acute stress events. A prolonged, severe stress can transition the acute phase of critical illness into multi-organ failure. Organ failure is however postulated to preserve basic cellular survival at the expense of higher functions by inducing a metabolic shutdown. This persists until the inciting event passes and recovery is possible \[[@CR3]\].

Critical illness may therefore represent the ultimate example of acute stress-related decompensation. Given the key role of the central nervous system, it could be predicted that sedating drugs, commonly utilised in the critically ill, will interfere with normal coordination of the stress response and thus generate abnormal outputs. If confirmed, this may contribute to the abnormal haemodynamics, metabolic disturbances and organ dysfunction observed in critical illness.

A reduction in sedation level alone confers a benefit for critically ill patients by way of reduced ventilator days, intensive care length of stay, duration of coma and mortality \[[@CR4]--[@CR9]\]. The Sedation Practices in Intensive Care Evaluation (SPICE)-III study (NCT01728558) aims to determine whether any mortality benefit can be derived from targeting light sedation utilising a protocolised sedation strategy. Pilot data from the SPICE-II study \[[@CR10]\] show that early goal-directed sedation (EGDS) results in a marked reduction in sedation level as compared to standard practice, until approximately day 4 of admission. The SPICE-III study offers the opportunity to study two similar groups of patients who may have differing levels of physiological stress as a result of differing sedation levels (EGDS strategy versus standard care). To investigate this hypothesis, we undertook a pilot study to outline temporal changes in a panel of blood tests that represent key efferent limbs of the stress system in response to critical illness and sedation. The combination of tests was selected for the panel based on a combination of factors, namely physiological relevance, minimum total required blood sample volume and cost, in order to demonstrate feasibility and to generate baseline data to inform protocol development for a randomised controlled study.

Methods {#Sec2}
=======

Design and patients {#Sec3}
-------------------

This pilot observational cohort study was conducted in a 12-bed mixed surgical/medical general intensive care unit. The institutional human research ethics committee gave permission for prospective consent from a patient surrogate. The study was registered (ACTRN12616001200471) and conducted between August and December 2015.

Inclusion and exclusion criteria were chosen such that the study population would mirror the likely patient population in the SPICE-III study. Where relevant, data from this pilot study were compared against the standard-care arm of the SPICE-II pilot study \[[@CR10]\] as this likely reflects the final population of the SPICE-III study. Sedation practice in the standard care arm of SPICE-II most likely reflects practice in this current study. Patients were included if they were admitted to the intensive care unit requiring invasive mechanical ventilation and likely to remain ventilated for more than 24 h. Patients were excluded if less than 18 years of age, pregnant, had been mechanically ventilated for more than 12 h, had been enrolled in the intervention arm of the SPICE-III study, or admitted with a primary cardiac diagnosis, brain lesion, drug overdose, burns, a mean arterial pressure \< 50 mmHg despite adequate resuscitation, fulminant hepatic failure, were in full-time residential nursing care prior to admission, death was felt to be imminent or inevitable, or it was unlikely the patient would to survive to 90 days.

Study outcome measures {#Sec4}
----------------------

The main outcome measures were to determine (i) baseline variability and (ii) temporal change in concentration of the components of a panel of blood tests (Table [1](#Tab1){ref-type="table"}) taken over a period of 5 days in the context of critical illness. These data would determine the feasibility of performing blood tests on patients enrolled in the SPICE-III study in terms of recruitment rate and adherence to a protocol of blood sampling.Table 1Panel of assays performedAldosteroneNoradrenalineTri-iodothyronine (FT3)AdrenalineTotal cholesterolb-type natriuretic peptide (BNP)High density lipoprotein (HDL) cholesterolTroponin I (TNI)TriglyceridesKetones

Study process {#Sec5}
-------------

Potentially eligible participants were identified by the ICU team caring for the patient. Once informed consent was obtained either from the patient or surrogate decision maker, patients were enrolled and blood drawn immediately from an indwelling arterial catheter. Blood sampling was repeated every 12 h for a period of 5 days. The samples were processed and analysed by the local hospital pathology laboratory. FT3 was analysed using competitive binding immunoenzymatic assay, TNI by two-site immunoenzymatic (sandwich) quantitative assay, triglycerides, total and HDL cholesterol were analysed by spectrophotometric timed endpoint assay (Beckman-Coulter Synchron Clinical Systems. Brea, CA, USA). Aldosterone was analysed by liquid chromatography with mass spectrometry (LC-MS/MS). Catecholamines were analysed by high performance liquid chromatography (HPLC) coupled with electrochemical detection (ECD). β natriuretic peptide (BNP) was analysed using an iSTAT point of care analyser (Abbott Point of Care Inc. Abbott Parl, IL, USA). Ketones were analysed by FreeStyle Optimum H Blood B-Ketone Test Strips™ (Abbott, Sydney, Australia). Baseline characteristics were recorded for each patient including demographics and co-morbidities. Daily records were kept of sedation level (Richmond Agitation Sedation Scale (RASS)), the severity of illness (sepsis-related organ failure assessment (SOFA) score) and medication (type and dose of sedative, analgesic and inotropic or vasoactive agents).

Statistical analysis {#Sec6}
--------------------

Values are reported as means with standard deviation for normally distributed variables and medians with interquartile ranges (IQRs) for non-normally distributed continuous variables and proportions for categorical variables. Comparisons between groups have been made using a chi-squared test for equal proportion or Fisher exact test where numbers were small. Where appropriate, linear regression analysis was undertaken to define the relationship between nominated predictor and outcome variables. Cross-sectional time series (panel) data were analysed using a mixed effect linear model with the patient as the panel variable. Validity of this technique was checked using a Hausman test. Significance of the regression slope (β) and its 95% confidence interval were reported. All models underwent residual diagnostics for distribution and homoscedasticity. For all analyses, the level of significance was set at *P* \< 0.05.

Results {#Sec7}
=======

Of the 49 patients who met all inclusion criteria, 12 were enrolled (Fig. [1](#Fig1){ref-type="fig"}). Baseline patient demographics and characteristics are shown in Table [2](#Tab2){ref-type="table"}. Patients were admitted from the emergency department (*n* = 5), general ward (*n* = 3), operating theatre (*n* = 2), medical emergency call from the ward (*n* = 1) and inter-hospital transfer (*n* = 1). There were no significant differences in baseline characteristics between this population and the standard care arm of the SPICE-II study.Fig. 1CONSORT diagram. Of the screened patients, 2 (3.9%) did not meet inclusion criteria, 33 (64.7%) met exclusion criteria and 4 (7.8%) were excluded based on medical decisionTable 2Patient characteristics and demographic dataPatient characteristicsSPICE-II standard arm (*n* = 16)All-SPICE (*n* = 12)*P* valueAge, year; mean (SD)61.6 (17.0)57.09 (16.30)0.486Male, % (*n*)9 (56%) (9)5 (41.67%)0.704Weight, Kg; mean (SD)87.0 (28.1)91.33 (27.68)0.688APACHE-II; mean (SD)18.6 (8.8)20.08 (10.26)0.685Admission source Ward referral, % (*n*)25.0% (4)33.3% (4)0.691 Operating theatre, % (*n*)25.0% (4)16.9% (2)0.673 Emergency department, % (*n*)43.7% (7)41.7% (5)\> 0.999 Inter-hospital transfer, % (*n*)6.25% (1)8.33% (1)\> 0.999Vasopressor during study, % (*n*)88% (14)92% (11)\> 0.999*APACHE II* acute physiology evaluation and chronic Health Evaluation II (11)

Feasibility of recruitment, feasibility of blood sampling {#Sec8}
---------------------------------------------------------

The recruitment rate was 0.77 patients per week. No consent was revoked. Eighty-nine percent (107/120) of all planned blood samples were obtained.

The time from eligibility to enrolment was a median (IQR) of 1.4 h (0.4--9.2), and the time from eligibility to the first blood sample was 4.8 h (2.0--10.6). Initial blood samples were taken within a median (IQR) of 0.7 h (0.2--2.35) of enrolment with subsequent blood sampling done within 0.0 h (0--0.3) of the identified sampling time point (Table [3](#Tab3){ref-type="table"}).Table 3Feasibility and clinical outcomesClinical outcomeSPICE-II -standard sedation limb (*n* = 16)All-SPICE OPS (*n* = 12)*P* valueTime from eligibility to enrolment (h), median \[IQR\]1.1 \[0.44--3.54\]1.4 \[0.36--9.19\]*P* = 0.71Time from eligibility to first blood draw (h), median \[IQR\]4.79 \[2.0--10.61\]Time from enrolment to first blood draw (h), median \[IQR\]0.655 \[0.23--2.353\]Samples obtained, % (*n*)89.2% (107/120)Interval from planned to actual sample draw time (h), median (IQR)0.0 (0--0.3)RASS − 2 to 1 first 48 h (%)38% (74/197)56% (33/59)0.016\*RASS − 3 to − 5 first 48 h (%)57% (112/197)41% (24/59)0.037\*Extubated within 7 days75% (12)75% (9)\> 0.999Ventilator free days at day 28, mean (SD)20.1 (10.1)20.07 (9.66)\> 0.999ICU LOS days, median \[IQR\]7.0 \[2.5--9.4\]6.45 \[4.44\]0.471ICU mortality, % (n)12.5% (2)8% (1)0.7423Hospital LoS, median \[IQR\]17.0 \[4.0--29.0\]21.15 \[11.5--37.5\]0.341Hospital mortality, % (n)12.5 (2/16)16.67 (2/12)\> 0.99990-day mortality, % (n)12.5 (2/16)16.67 (2/12)\> 0.999All results are presented as median \[IQR\]

Physiological parameters {#Sec9}
------------------------

Physiological markers of stress, namely temperature, heart rate and mean arterial pressure (MAP), are shown in Fig. [2](#Fig2){ref-type="fig"}. There was a significant drop from a median (IQR) heart rate from 82.5 bpm (76.3--97.5) to 68.5 bpm (55.5--79) (*p* = 0.023) and an increase of median (IQR) mean arterial pressure from 72.5 mmHg (64--77.5) to 95.5 mmHg (86.5--110.8). Median (IQR) core body temperature was raised at 37.7 °C at baseline with no significant change over the study period (*p* = 0.16).Fig. 2Physiological markers of stress. Median and interquartile range for each time point. **a** Temperature. **b** Heart rate. **c** Mean arterial pressure

Blood results {#Sec10}
-------------

### Metabolic biomarkers (Fig. [3](#Fig3){ref-type="fig"}) {#Sec11}

Total cholesterol and triglycerides showed a small but statistically significant rise over time (both *p* \< 0.001). HDL cholesterol levels were subnormal at baseline and displayed no significant change over time (*p* = 0.99). There was a high degree of inter-individual baseline variability in ketone levels at baseline with a significant decrease in median level over the study period (*p* \< 0.001). Only one patient received total parenteral nutrition (TPN) during the study; exclusion of this patient's results had no significant impact on any of the above results.Fig. 3Cardiac profile. Median and interquartile range for each time point. Normal range is represented by the shaded area. **a** Troponin I, **b** β-Natriuretic peptide

Baseline median lactate levels (1.05 mmol/l \[0.725--1.5\]) were within the normal range and did not vary significantly (*p* = 0.38) over the course of the study. Standard base excess however increased over time (*p* \< 0.001).

### Cardiac biomarkers (Fig. [4](#Fig4){ref-type="fig"}) {#Sec12}

In patients without a primary myocardial injury troponin I (TNI) level fell within the normal range and showed no significant change over time (*p* = 0.93). Three patients that suffered myocardial injury secondary to ischaemia, cardiac arrest and chest trauma had correspondingly elevated troponin levels. These patients were excluded from the analysis as they represent a discrete subgroup. Similarly, BNP levels fell mostly within the normal range and showed no overall trend over time (*p* = 0.79). One patient was excluded from the analysis due to a diagnosis of acute congestive cardiac failure.Fig. 4Metabolic profile. Median and interquartile range for each time point. Normal range is represented by the shaded area. **a** total cholesterol, **b** HDL cholesterol, **c** Triglycerides, **d** lactate, **e** ketones, **f** base excess. \* upper limit for individuals at low cardiovascular risk. \$ upper limit for individuals at high cardiovascular risk

### Hormonal profile (Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}) {#Sec13}

Plasma adrenaline levels fell within the normal range throughout and showed no significant variation over time (*p* = 0.93). In contrast, noradrenaline levels were over tenfold higher than normal at baseline but fell by the end of the study period (*p* = 0.031). All but one patient was prescribed norepinephrine with a median \[IQR\] total dose of 5.2 mg \[3.6--18.8\] for a median of 3.5 days \[2.75--7.25\]. Noradrenaline levels correlated significantly with the administered noradrenaline dose (*p* \< 0.001). Three patients received vasopressin. No other vasopressor or inotrope was used.Fig. 5Hormone profile. Median and interquartile range for each time point. Normal range is represented by the shaded area. **a** Adrenaline. **b** Noradrenaline. **c** FT3. **d** AldosteroneFig. 6Correlation of administered noradrenaline dose (mcg/min) and plasma noradrenaline level (pmolL^−1^)

Triiodothyronine (FT3) levels were marginally low at baseline and showed no variation over time (*p* = 0.40). Aldosterone levels fell well within the normal range for supine patients but did decrease significantly over time (*p* = 0.001).

### Sedation depth {#Sec14}

A mixture of sedating agents was used: 1 (8%) received dexmedetomidine, 10 (83%) received propofol and 10 (83%) received midazolam. For analgesia, 11 (92%) received fentanyl and 5 (42%) morphine. During the first 48 h, there was a significant difference in the level of sedation in this study as compared to the standard care arm of the SPICE-II study. Of all RASS scores, 33 of 59 (56%) were in the light sedation range versus 74 of 197 (38%) in the SPICE-II study (*p* = 0.015). On the other hand, 24 of 59 (41%) were in the deep sedation range compared to 112 of 197 (57%) in the SPICE-II standard care group (*p* = 0.03) (Table [3](#Tab3){ref-type="table"}) (Fig [7](#Fig7){ref-type="fig"}). A similar dose of propofol (9.6 mg/kg/day \[2.7--30.7\]) was used as compared to that used in the SPICE-II study (11.3 \[6.8--19.3\] (*p* = 0.87); however, the dose of fentanyl was significantly higher (11.1 mcg/kg/day \[8.1--26.2\] versus 0 mcg/kg/day \[0--2.7\] in the SPICE-II study. There was no significant difference in the dose of morphine used as compare to the SPICE-II study (*p* = 0.576) (Table [4](#Tab4){ref-type="table"}**)**.Fig. 7Richmond Agitation Sedation Scale (RASS) scores in the first 48 h. In the first 48 h, a total of 59 RASS scores were performed. Most of the scores were in the light sedation range (55%)Table 4Cumulative dose/kg body weight and duration of treatment with sedatives and analgesic agents throughout the study periodDrugs givenStandard care *n* = 16No. treatedAll-SPICE *n* = 12No. treated*P* valueDexmedetomidine (mcg/kg/day)0 \[0--0\]10 \[0--0\]10.7460Time on dexmedetomidine (day)0 \[0--0\]0 \[0--0\]\> 0.9999Propofol (mg/kg/day)11.33 \[6.77--19.29\]169.63 \[2.74--30.7\]110.8667Time on propofol (day)2.5 \[2.0--4.5\]1.0 \[0.5--3.0\]*0.0139* **\***Midazolam (mg/kg/day)0.037 \[0--0.18\]80.010 \[0--1.17\]100.466Time on midazolam (day)0.5 \[0.0--2.0\]2.0 \[1.0--4.0\]*0.0283* **\***Fentanyl (mcg/kg/day)0 \[0--2.67\]711.14 \[8.08--26.18\]11*0.0002* **\***Morphine (mg/kg/day)0.153 \[0--0.59\]100.20 \[0--1.99\]60.576Values are expressed as median \[interquartile range\]

Discussion {#Sec15}
==========

The primary objective of this study was to demonstrate that a larger randomised sub-study of the effects of sedation upon the various axes of the stress system is both practical and feasible. This study utilised inclusion and exclusion criteria similar to that required for the SPICE-III study. The enrolment of 12 patients was completed over a 15-week period. All were recruited early within the time window of the SPICE-III study, and the delay to first blood draw was negligible. One hundred nine (90.8%) of the required 120 blood tests were performed, with loss of samples due to lack of indwelling vascular access device or discharge from the intensive care unit. These data therefore demonstrate that recruitment as a sub-study of the SPICE-III study is feasible and adherence to study protocol is likely to be excellent.

The study population closely mirrored the population from the SPICE-II pilot study that informed the design of the larger SPICE-III study. Sedation practice at the time in the participating unit utilised midazolam and propofol in preference to dexmedetomidine with a standard prescription of a RASS target range and no protocolised weaning regimen. This practice most resembled the standard care arm of the SPICE-II study. Consequently, all comparisons are made to these patients only. There was a significantly lighter level of sedation reached in our study with a correspondingly lower propofol dose. This difference likely reflects unit practice. For the follow-up study, the utilisation of multiple other sites may negate this difference.

We chose a number of variables thought likely to represent key efferent limbs of the stress axes to study changes over time in critically unwell patients following the commencement of sedation to facilitate mechanical ventilation. Each behaved differently during the observation period. Several changed significantly, reflecting a predicted pattern of stress response secondary to critical illness and its progressive resolution over time. Physiological parameters demonstrate a modest level of stress at baseline with an improvement over the time course of the study. Ketones, aldosterone, and lactate were elevated at baseline and fell to normal levels. There was also a significant drop in noradrenaline level over time; however, this is at least partially explained by reductions in the dose of administered norepinephrine. Triglyceride levels were at the upper limit of normal at study commencement and increased further during the study period. This reflects the normal response to critical illness and is a manifestation of increased lipolysis. Propofol was used in low doses only and for a short period so is unlikely to have contributed significantly to triglyceride levels. On the other hand, HDL cholesterol levels were low, a finding reflected by many other studies of critical illness \[[@CR11], [@CR12]\] and remained low during the time course of the study.

Conclusion {#Sec16}
==========

This study has demonstrated that conduct of a larger sub-study of the SPICE-III study assessing the stress response of critical illness and modification by sedation regimen is feasible. The study has demonstrated a predictable trend of variation of the components of the blood panel during the evolution of critical illness during an intensive care admission following commencement of mechanical ventilation. In order to determine the effects of sedation level upon the components of the blood test panel, it is advisable to undertake sequential blood tests over several days.
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